The PsychENCODE project by Akbarian, Schahram et al.
The PsychENCODE project
The PsychENCODE Consortium*, Schahram Akbarian, Chunyu Liu, James A Knowles, 
Flora M Vaccarino, Peggy J Farnham, Gregory E Crawford, Andrew E Jaffe, Dalila Pinto, 
Stella Dracheva, Daniel H Geschwind, Jonathan Mill, Angus C Nairn, Alexej Abyzov, 
Sirisha Pochareddy, Shyam Prabhakar, Sherman Weissman, Patrick F Sullivan, Matthew W 
State, Zhiping Weng, Mette A Peters, Kevin P White, Mark B Gerstein, Geetha Senthil, 
Thomas Lehner, Pamela Sklar, and Nenad Sestan
Geetha Senthil: geetha.senthil2@nih.gov; Thomas Lehner: tlehner@mail.nih.gov; Pamela Sklar: 
pamela.sklar@mssm.edu; Nenad Sestan: nenad.sestan@yale.edu
Abstract
Recent research on disparate psychiatric disorders has implicated rare variants in genes involved 
in global gene regulation and chromatin modification, as well as many common variants located 
primarily in regulatory regions of the genome. Understanding precisely how these variants 
contribute to disease will require a deeper appreciation for the mechanisms of gene regulation in 
the developing and adult human brain. The PsychENCODE project aims to produce a public 
resource of multidimensional genomic data using tissue- and cell type–specific samples from 
approximately 1,000 phenotypically well-characterized, high-quality healthy and disease-affected 
human post-mortem brains, as well as functionally characterize disease-associated regulatory 
elements and variants in model systems. We are beginning with a focus on autism spectrum 
disorder, bipolar disorder and schizophrenia, and expect that this knowledge will apply to a wide 
variety of psychiatric disorders. This paper outlines the motivation and design of PsychENCODE.
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Noncoding DNA sequences are believed to comprise over 90% of the human genome1,2 and 
their roles in the spatial, temporal and quantitative regulation of gene expression in different 
organisms and tissues have been well recognized for decades3–5. However, a comprehensive 
catalog of noncoding elements is lacking, and the full extent of contributions of these 
elements to various biological functions has remained unclear and under-investigated. 
Recent technological and analytical advances have allowed many large-scale studies, 
including the Encyclopedia of DNA Elements (ENCODE) Consortium6 and the Roadmap 
Epigenomics Mapping Consortium7 (REMC), to begin systematic characterization of 
genomic elements of the human genome and of genome-wide regulatory relationships. 
These studies substantiated previous findings that many human non-protein-coding 
sequences may be actively transcribed into noncoding RNAs or serve as functional cis-
regulatory elements such as promoters, enhancers and insulators, often in a cell- and tissue-
specific way. The functional relevance of noncoding sequences is also supported by linkage 
studies, genome-wide association studies (GWAS) and targeted and whole-genome 
sequencing studies, which have repeatedly shown that common genetic variations associated 
with human diseases cluster in putative regulatory regions4,8. Moreover, several studies, 
including the Genotype-Tissue Expression (GTEx) Consortium9, have shown that 
noncoding genetic variation is associated with expression differences across various human 
tissues. Bridging efforts across various studies using a well-phenotyped, disease-relevant 
population is therefore needed to provide a mechanistic link between disease-associated 
genetic variants and disease phenotypes.
Psychiatric disorders such as autism spectrum disorder (ASD), bipolar disorder and 
schizophrenia are often devastating illnesses, with high personal and societal costs and 
limited treatment options. They show distinct symptomatology, age of onset and 
progression, and are highly heritable, with a complex, polygenic risk architecture10,11. The 
multitude of discrete loci involved makes identifying the molecular and cellular mechanisms 
underlying a disease problematic and hampers development of therapies. Additionally, while 
the functional implications of rare variations in coding sequences are usually readily 
apparent, the effects of the more common noncoding variants can be challenging to intuit8. 
Therefore, to understand disease mechanisms, it is necessary to perform comprehensive 
analyses of the regulatory regions, epigenetic modifications and gene expression patterns 
present across different ages, regions and cell types in both the healthy and the disease-
affected human CNS. Unfortunately, so far, neither such a comprehensive data set nor any 
systematic characterization of the functional genomic elements and noncoding RNAs linked 
to psychiatric disorders is available. The PsychENCODE project was founded to begin to 
rectify this deficiency and to facilitate research on psychiatric diseases; a list of participating 
institutions and groups is available at http://www.psychENCODE.org/.
The necessity and difficulties of studying human brain
Vertebrate and invertebrate model systems offer powerful means of dissecting molecular, 
cellular and circuit functions at a level often not possible in humans and thus provide a 
necessary adjunct to study of the human brain. However, the human brain is not simply a 
larger replicate of the CNS of rodents or other commonly studied experimental species and 
certain aspects of its development and physiology are not well recapitulated in model 
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organisms. The utility of model organisms is also limited by our evolutionary distance from 
these organisms. While coding sequences are generally conserved across species, noncoding 
sequences may be subject to less selective pressure and, as such, regulatory elements, 
transcriptional regulatory networks and gene expression patterns may differ between 
species12–15. Moreover, null mutations in human and mouse orthologous genes can result in 
different phenotypes, including the complete absence of a neural phenotype in one of the 
two species16. Therefore, psychiatric disorders need to be understood and characterized 
within the context of the human brain.
Unfortunately, the human brain is difficult to study for many reasons. The difficulty of 
obtaining high-quality post-mortem human brain tissue (healthy or otherwise) and the lack 
of sufficient sample sizes to overcome experimental and individual variability make the 
application of genomic technologies particularly challenging. The age of onset and 
progression of major psychiatric disorders also varies, necessitating the study of the 
temporal dynamics of human brain development and recognition of the developmental 
context of psychiatric disorders. This problem is further compounded by the extensive 
molecular, cellular and temporal differences in regional brain architecture17–20. Even within 
a functionally distinct region, there is usually remarkable cellular heterogeneity, with a 
myriad of molecularly, morphologically and functionally distinct cell types. We are only 
beginning to develop methods to systematically isolate specific cell types from brain tissue; 
these techniques are labor intensive and low throughput, and, unfortunately, cell cultures do 
not accurately represent brain tissue complexity. The necessity of using archival healthy and 
disease-affected post-mortem brains, uncertainties in when new tissue specimens will be 
available and the circumstances of the tissue donor’s death (which can dramatically affect 
the stability of nucleic acids and proteins) further compound these problems. These and 
other challenges have hindered wider usage of post-mortem human brain tissues in basic 
neuroscience, genomics and psychiatric disorder research. Overcoming these challenges 
requires integration of expertise across disciplines (for example, biobanking, human 
developmental neurobiology, molecular biology, genetics, genomics and high-throughput 
analyses, computational and systems biology, biostatistics, evolutionary biology, mouse 
genetics and stem cell biology), as well as the development of new approaches to generate 
and make the multidimensional genomic data from healthy and disease-affected human post-
mortem brain tissues more readily available to the wider community.
The goals and organization of the PsychENCODE project
Key goals of the PsychENCODE project are to provide an enhanced framework of 
regulatory genomic elements (promoters, enhancers, silencers and insulators), catalog 
epigenetic modifications and quantify coding and non-coding RNA and protein expression 
in tissue-and cell-type-specific samples from healthy (neurotypical) control and disease-
affected post-mortem human brains (Fig. 1). These efforts will be complemented with 
integrative analyses, as well as with functional characterizations of disease-associated 
genomic elements using human neural cells derived from induced pluripotent cells (iPSCs) 
or the developing mouse brain. The PsychENCODE Consortium represents, to our 
knowledge, the single largest integrated collaborative effort in neuroscience and psychiatry 
to collectively analyze genomic regulatory elements in a large cohort of well-curated human 
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brains. The consortium brings together experts in psychiatric disorders, neurodevelopment, 
biobanking, genetics, genomics, data integration and innovative large-scale analyses who 
will together provide critical insights into the complexity of functional genomic elements. In 
addition, these experts have consolidated approximately 1,000 well-curated, high-quality 
postmortem brain specimens, both healthy and disease-affected, spanning multiple 
developmental periods. This intersection of experiences and resources, including funding 
from individual investigator grants, will allow the PsychENCODE Consortium to contribute 
to the greater understanding of psychiatric disorder genomics and mechanisms.
Disease focus areas
The PsychENCODE project will focus on three major psychiatric disorders: ASD, bipolar 
disorder and schizophrenia. Schizophrenia arises during adolescence and adulthood, and 
diagnosis is based entirely on clinical symptoms, including delusions, hallucinations, 
anhedonia, social withdrawal, executive function deficits and working memory 
impairments21,22. Hallmark symptoms of bipolar disorder, which also arises during 
adolescence and adulthood, include inappropriately elevated mood, rapid speech and 
decreased need for sleep. These often alternate with episodes of depression, psychotic 
symptoms similar to those of schizophrenia, and cognitive problems. More than 100 years of 
family and twin studies have demonstrated substantial heritability for both schizophrenia 
and bipolar disorder, with estimates of genetic liability ranging from 64 to 67% for 
schizophrenia and 59 to 62% for bipolar disorder23,24. GWAS have identified common 
variants in over 100 loci for schizophrenia and 8 for bipolar disorder11,25,26 that are 
associated with risk. Rates of rare inherited and de novo copy number variations are elevated 
in schizophrenia (less so in bipolar disorder), with many conferring high risk27. The two 
diseases also co-occur in families more frequently than expected, and studies suggest there 
is more than 50% overlap in genetic susceptibility23.
ASD arises during early childhood and is characterized by persistent impairments in 
reciprocal social communication, accompanied by restrictive, repetitive behaviors, interests 
or activities28,29. ASD is highly heritable, with rare genetic variations including copy 
number variations, de novo point mutations, and insertions or deletions in protein-coding 
regions of the genome30,31 contributing to susceptibility. To date, studies of de novo exonic 
point mutations have highlighted chromatin remodeling, synaptic structure and function, 
early embryonic genes and targets of the fragile X mental retardation protein, an RNA-
binding protein27,30,31. Recent work has provided strong empirical evidence that single 
nucleotide polymorphisms (SNPs) and other common variations affect population risk32. 
Several studies have shown a genetic overlap of de novo variants in genes encoding 
chromatin modeling proteins or glutamatergic post-synaptic proteins between schizophrenia 
and ASD11,30,33,34, and common SNPs are shared between schizophrenia and bipolar 
disorder7. Together, these findings suggest both convergent and distinct underlying 
pathogenic mechanisms in these and possibly other psychiatric disorders, further 
strengthening the case for increasing the attention paid to such mechanisms and the need for 
strategic consolidation of resources.
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Human brain regions, developmental periods and cell types
Our investigations will prioritize brain regions and cell types that previous research has 
suggested contribute to ASD, bipolar disorder and schizophrenia. These include multiple 
regions of the cerebral neocortex (the dorsolateral prefrontal cortex, anterior cingulate cortex 
and inferior temporal cortex), hippocampus, amygdala, caudate nucleus, nucleus accumbens 
and cerebellar cortex21,22,28. Most of the post-mortem tissues will be obtained from brain 
banks or are already part of the consortium investigators’ tissue collections. To address 
cellular heterogeneity, PsychENCODE in its first phase will primarily focus on neurons 
versus non-neuronal cells, using fluorescence-activated nuclear sorting (FANS) to collect 
molecularly identifiable cell populations from archived and prospectively collected post-
mortem human brains35. FANS will be conducted using the NeuN antibody, raised against 
the pan-neuronal nuclear protein RBFOX3. In addition, exploratory assessment of more 
neural subtypes for which suitable antibodies against nuclear antigens (which are a 
prerequisite for FANS) are available and emerging single-cell genomic technologies will 
also be applied to explore cellular heterogeneity.
To address the developmental changes that may influence disease progression, our studies of 
the aforementioned brain regions and cell types will also be conducted in the developing 
human brain, including prenatal and early postnatal brain specimens. Additionally, to 
complement the use of post-mortem human brain samples, we will conduct parallel 
investigations of neural cells derived from two model in vitro systems, induced pluripotent 
stem cells (iPSCs) and cultured neuronal cells derived from olfactory neuroepithelium 
(CNON cells). iPSC-derived neural cells will be used to model human neurodevelopment in 
a specific genetic background and to investigate regulatory, epigenetic and transcriptional 
landscapes during cell differentiation. A previous study has shown that human iPSC-derived 
forebrain neurons cultured as organoids display transcriptome profiles and cellular 
phenotypes corresponding to those of the early-fetal human forebrain36, facilitating study of 
otherwise inaccessible stages of prenatal development. Conversely, primary neural 
progenitor CNON cells37 are an attractive cell culture system that enable both strict 
environmental control and a large volume of material to be obtained relatively easily from 
healthy people and patients. Moreover, CNON cells can be used to study molecular 
alterations associated with brain disorders, including schizophrenia37. These in vitro cellular 
systems also allow modeling of genetic variants using genome-editing techniques and 
comparison with the post-mortem brain–derived findings.
Studies in evolutionary and developmental biology have shown that some phenotypic 
variations among species are driven by the evolution of gene regulatory networks, including 
changes in transcription factors and cis-regulatory elements12–14. The same regulatory 
networks are also affected in many human diseases. Therefore, complementary analyses of 
post-mortem brains of rhesus macaque and chimpanzee, two closely related nonhuman 
primates, will be conducted to identify genomic elements that may be conserved or distinct 
across species. Better annotation and discovery of regulatory elements in the brains of other 
species will improve our ability to interpret variations in cis-regulatory elements and the 
evolutionary conservation of those elements.
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According to some estimates, the human genome harbors some 400,000 putative enhancers 
and 70,000 promoters6. To identify active cis-regulatory regions relevant to psychiatric 
diseases, the consortium will assay for the hallmark features—chromatin accessibility, 
nucleosome depletion and enrichment for certain post-translational histone modifications— 
of these regions in relevant brain tissues and cells. Chromatin immunoprecipitation coupled 
with next-generation sequencing (ChIP-seq) has been extensively applied to map histone 
modifications and transcription factor binding sites in cell lines6 and in brain tissue7,13,14. 
Enrichment for histone 3 Lys4 trimethylation (H3K4me3) and histone 3 Lys27 acetylation 
(H3K27ac) will be assayed to identify putative active promoters and enhancers, respectively, 
To identify open chromatin regions, we will take advantage of the small amounts of tissue 
required for the assay of transposase-accessible chromatin (ATAC-seq)38. This assay will be 
optimized using freshly frozen human brains.
One of the challenges of studying regulatory regions is finding the target genes of those 
regulatory regions: because higher order chromatin conformations such as chromosomal 
looping allow transcriptional control across considerable genomic distances and sometimes 
from locations as remote as another chromosome39, functionally linking cis-regulatory 
elements such as enhancers to downstream targets can be difficult. Chromosome 
conformation capture39 (also known as 3C), a standard approach to map chromosomal loops 
and Hi-C, a high-throughput adaptation of 3C, will be part of PsychENCODE efforts. 
Enhancer function will be further studied using mouse transgenesis and the self-transcribing 
active regulatory region sequencing (STARR-seq)40 assay to measure the activity of 
multiple enhancers simultaneously.
Methylation of DNA, at CpG and non-CpG dinucleotides, will be assayed by whole-genome 
bisulfite sequencing to obtain genome-wide DNA methylation profiles during development 
and late adolescence, when most neuropsychiatric illnesses first manifest. Nucleosome 
occupancy and, methylome sequencing (NOMe-seq)41, a recently developed assay that 
provides both a nucleosome footprint and a DNA methylation profile for a DNA strand, will 
also be applied.
The PsychENCODE consortium will quantify both coding and noncoding RNA by RNA-seq 
and long-read sequencing (Iso-seq). Ribosome footprinting and micro-western arrays 
coupled with reverse-phase protein arrays (MWA-RPPA) will be used to reveal the portions 
of RNA that are directly translated into peptides and proteins and to quantify protein levels.
Another important goal of the PsychENCODE consortium is to systematically evaluate 
variations in major epigenomic features within a well-phenotyped human population. 
ENCODE and REMC generated reference maps from a variety of control tissues and cell 
types, but these studies did not focus on the impact of genetic variation on chromatin state 
and structure. Likewise, GTEx identified expression quantitative trait loci (eQTLs) from a 
variety of human tissues, but focused primarily on samples from healthy individuals that 
have not been extensively phenotyped9. PsychENCODE will stand at the interface of these 
efforts by assembling epigenomic and transcriptomic data sets from approximately 1,000 
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post-mortem brains from healthy controls or individuals affected with schizophrenia, bipolar 
disorder or ASD. To this end, genotype data will be available either from genome-wide SNP 
arrays or by whole genome sequencing.
Data analysis
Analysis of the PsychENCODE data sets will be pursued as a joint effort by all individual 
groups and by the PsychENCODE data analysis core. To enable comparison and integration 
of the data generated by all groups, the data analysis core will normalize the data to remove 
batch effects, establish uniform data processing pipelines and build calibration resources for 
all assays. Established processing pipelines and data quality control metrics for major data 
types such as RNA-seq, ChIP-seq of transcription factors and histone marks, whole-genome 
bisulfite sequencing and Hi-C will be adapted for the data generated by the PsychENCODE 
Consortium; new pipelines will be developed for NOMe-seq and ATAC-seq.
In addition to analyzing individual data sets, an important goal of the PsychENCODE 
project is to integrate multiple data modalities to identify global mechanisms relevant to 
disease. Having a large sample size will provide sufficient statistical power to reliably detect 
different types of genomic elements active in the developing and adult human brain and 
those that are altered in psychiatric disorders. Data sets measuring transcript abundance will 
be integrated with maps of regulatory regions, providing putative disease-, tissue-or cell-
type-specific relationships between cis-regulatory elements and gene expression. DNA 
variations that affect chromatin state (epigenetic quantitative trait loci, or epiQTLs), 
transcript abundance (expression QTL, or eQTLs) and protein expression (pQTLs) will also 
be identified by integrating genotyping information (Fig. 1). Histone acetylation QTLs 
(haQTLs) will be identified with high sensitivity from ChIP-seq data by jointly scoring 
allelic imbalance and peak height variation in a cohort; regulatory variants identified in this 
manner are strongly enriched for linkage with disease-causing variants42. In all QTL 
analyses, known confounding factors such as age, sex and technical covariates will be 
corrected for and unidentified confounding factors will be minimized through principal 
component analysis or other methods. Because SNP-associated eQTLs in the brain are 
significantly enriched in GWAS of multiple psychiatric disorders43,44, RNA quantification 
data will be analyzed in conjunction with genotype data to identify eQTLs associated with 
brain regions in both normal and disease cohorts. pQTLs will be mapped using the same sets 
of samples as in the eQTL analyses. We expect that some pQTLs will be traced back to 
eQTLs. However, many pQTLs are not explained by eQTLs45, but rather by effects of the 
genetic variation on translational control or regulation of protein stability. Our pQTL 
analysis will identify such effects.
Many studies have shown that cis-eQTLs, methylation QTLs, DNase I sensitivity QTLs, 
haQTLs and pQTLs have large effect sizes that can be detected in less than 100 
samples9,42,46,47. It is expected that other epiQTLs will have similar number and magnitude 
of effects. PsychENCODE, which includes data from nearly 1,000 individuals, will allow 
detection of cis-QTLs and also opens the possibility of detecting trans signals that require 
larger sample sizes. PsychENCODE will thus have similar statistical power to that of GTEx, 
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which is examining a similar number of individuals for cis and trans eQTLs in a variety of 
other tissues.
Data integration will be performed initially for the individual diseases. First, the extent and 
nature of inter-individual differences will be characterized. Second, case-control differences 
will be investigated. Third, association with risk of disease will be tested and, where 
possible, these data will be used to refine SNP association by prioritizing individual genes 
and causal alleles in nominally associated GWAS regions48. For assays common across 
disorders (for example, RNA-seq and some histone modifications), well-powered sample 
sizes approaching several hundred controls will be achieved and cross-disorder analysis will 
be performed.
The initial comparisons will use classical, primarily pairwise, methods followed by systems-
level analyses to identify gene regulatory networks. Coexpression networks, such as those 
based on weighted gene coexpression network analysis, permit construction of 
networks12,17,18,29–31,34,36 using expression data obtained in brain, in cellular fractions and 
in cellular models. Identified gene coexpression networks will be refined by incorporating 
diverse data types, including noncoding RNA expression patterns, splicing and ChIP-seq 
data to identify those regulatory networks most relevant for psychiatric disease. The 
comparison of gene coexpression networks between normal and disease-affected brains 
represents another platform that allows prioritization of gene variants and associated 
networks as potential candidates for functional validation using mouse models and iPSCs. 
Comparison of these gene networks with large sample cohorts available through 
PsychENCODE will also allow population-level analyses.
Finally, the PsychENCODE project will avail itself of data from other consortia, including 
BrainSpan (http://www.brainspan.org/), CommonMind (http://www.commonmind.org/), 
ENCODE (http://www.encodeproject.org/), REMC (http://www.roadmapepigenomics.org/), 
GTEx (http://www.gtexportal.org/home/) and the Psychiatric Genomics Consortium (PGC; 
http://www.med.unc.edu/pgc/). To allow comparison of these data sets, parameters in the 
processing pipelines of different projects will be evaluated and calibrated by the data 
analysis core. In addition, we will compare the functional genomic elements identified 
across these projects, with reference to the specific tissues and cell types studied by these 
consortia. Major differences in identified genomic elements, if any are detected, will be 
further examined to determine whether they are due to the underlying raw data or analytical 
approaches. After building the calibration resources, PsychENCODE data will be compared 
against data from tissues other than brain to identify transcripts and enhancers specific to 
brain regions and cell types, and such information will be used to deconvolve cellular 
diversity and variability in post-mortem tissues.
Functional characterization of disease-associated elements
The functional contribution of regulatory elements to the development, evolution, function 
and pathogenesis of the brain is well recognized, but still under-studied by 
neuroscientists13,14,49. We will assess consequences of noncoding disease-associated 
variants on DNA-binding protein occupancy, epigenetic modifications and gene expression 
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in the context of neurodevelopment by engineering select variants into mice and/or isogenic 
human iPSCs using CRISPR-based genome editing tools. Variants will be prioritized on a 
number of criteria, including the strength of association between any given variant and 
disease, the likelihood that the variant perturbs cis-regulatory elements or genes known to be 
differentially expressed in disorders or active in the developing human brain, the proximity 
of the variant to previously identified disease-related genes or loci, the presence of binding 
sites for relevant disease-related transcription factors within the putative regulatory element, 
the relative impact of the variant on high-throughput reporter gene activity and the 
evolutionary conservation of the putative regulatory element.
iPSCs provide an in vitro system on a controlled genetic background that has been used to 
study molecular and cellular alterations associated with psychiatric disorders36,50. 
Multidimensional genomic maps complementary to those generated by studies of the post-
mortem human brain will be generated using human iPSCs differentiated into cortical 
organoids containing neural progenitors, excitatory projection neurons and inhibitory 
interneurons, thus validating this system as a model to study human brain development. 
Then iPSC-derived organoids carrying control or disease variants and their constituent cell 
types isolated by FANS will be analyzed at different time points during differentiation and 
the resulting data compared to that generated from post-mortem tissue. Additionally, to 
account for sex-related differences and off-target effects, iPSCs derived from both male and 
female donors will be used and each mutation will be made in two independent isogenic 
iPSC clones.
The mouse model provides a physiologically and developmentally relevant in vivo system. It 
will be used primarily for disease variants that occur in genomic regions that are highly 
conserved between species and that have already been validated using iPSCs. Comparisons 
between the results generated from human iPSCs and mouse models will demonstrate the 
extent to which disease variants converge on common molecular and cellular mechanisms 
across development, species and cell types. Additionally, the development of these mouse 
models will provide the basis for future studies on neural circuits and behavior.
Data accessibility
The PsychENCODE Consortium will share information among consortium members and the 
broader research community through a website (http://www.psychENCODE.org/) and a 
knowledge portal (http://www.synapse.org/pec). The website will provide descriptive 
information about each project, news about the consortium and up-to-date information on 
tissue banks, protocols and sample sizes. The knowledge portal, developed by the 
PsychENCODE data coordination core at Sage Bionetworks, is designed to provide a 
centralized environment for accessing data, protocols and analytical output to enable 
collaboration among and beyond consortium members.
Data will be released to the broader research community at six-month intervals beginning in 
January 2016. Access to data derived from human samples will be shared using a controlled 
access mechanism that complies with regulatory requirements and governance policies 
regarding protection of personal information. Tissue samples from the investigators’ 
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collections, when available, will also be obtainable upon request using similar guidelines. 
CNON cells, fibroblasts and iPSCs will be made available through the NIMH Repository 
and Genomics Resource (NIMH-RGR; http://www.nimhgenetics.org/). PsychENCODE 
investigators will ensure that data can be visualized through genome browsers such as the 
UCSC Genome Browser and/or IGV.
Conclusions
The main goals of PsychENCODE are to build comprehensive spatio-temporal reference 
maps of genomic elements active in healthy and disease-affected brains, to assess population 
epigenetic variations of human brains and to functionally characterize disease-associated 
variants. The PsychENCODE Consortium brings together distinct projects that will apply 
comprehensive, unbiased, complementary and non-overlapping approaches to gain insight 
into the roles of noncoding elements in developing and adult, healthy and disease-affected 
human brains on a population scale. Although some existing consortia (REMC, GTEx and 
BrainSpan) have included studies of the healthy human brain, the PsychENCODE project is 
unlike these efforts in that it will integrate disease-associated variants, changes in gene and 
protein expression, noncoding DNA elements and many disease phenotypes. Furthermore, 
PsychENCODE will be the first consortium to compare neuronal and non-neuronal 
transcriptomes and epigenomes from post-mortem brains of donors with psychiatric 
phenotypes with similar data sets obtained from tissue homogenates, as a starting point for 
exploring cell-type-specific regulation of genome organization and function across the 
timespan and disease states. It will bring together a large collection of well-curated healthy 
and disease-affected human brains over the course of development and adulthood. The large 
sample sizes will generate population-level genomic and epigenomic data for both control 
and disease-affected brains. The PsychENCODE project will also complement these 
approaches with studies in human neural cell culture systems and in developing nonhuman 
primate brains. The consortium’s cross-species and cross-model studies will reveal genomic 
risk factors that may be central to human neuropathology in a comprehensive fashion 
beyond the purview of any individual laboratory. We expect that the genome-scale data sets 
provided by the PsychENCODE project will facilitate the identification and functional 
characterization of genomic elements active in the developing human brain, provide a new 
foundation on which to build and test hypothesis derived from the data and greatly enhance 
our understanding of the mechanisms underlying complex psychiatric disorders.
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An overview of the PsychENCODE project, showing a schematic of the proposed data types 
and analyses. The genomic data will be generated from tissues, sorted nuclei and cell culture 
systems. For each data type, regional, cell-type, developmental, sex-specific and disease-
related differences will be identified. Different data modalities will be integrated to identify 
global mechanisms relevant to disease. Bi-directional flow between genetic information and 
functional data define eQTLs, epiQTLs and pQTLs, which in turn will assist in prioritizing 
and refining disease. The specific diseases of interest are shown in outer circle; cross-
disorder analysis will also be performed for all data types.
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